MilliporeSigma
All Photos(1)

Documents

H-001

Supelco

Hydrochlorothiazide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

All Photos(1)
Empirical Formula (Hill Notation):
C7H8ClN3O4S2
CAS Number:
58-93-5
Molecular Weight:
297.74
EC Number:
200-659-6
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

Gene Information

human ... SLC12A3(6559)

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PHR10321314009H1200000
Hydrochlorothiazide solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-001

Hydrochlorothiazide solution

Hydrochlorothiazide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1032

Hydrochlorothiazide

Hydrochlorothiazide United States Pharmacopeia (USP) Reference Standard

USP

1314009

Hydrochlorothiazide

Hydrochlorothiazide European Pharmacopoeia (EP) Reference Standard

H1200000

Hydrochlorothiazide

form

liquid

form

-

form

-

form

-

packaging

ampule of 1 mL

packaging

-

packaging

-

packaging

-

manufacturer/tradename

Cerilliant®

manufacturer/tradename

-

manufacturer/tradename

USP

manufacturer/tradename

EDQM

concentration

1.0 mg/mL in methanol

concentration

-

concentration

-

concentration

-

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

technique(s)

-

technique(s)

-

General description

Hydrochlorothiazide is a calcium-sparing diuretic used for treatment of edema and hypertension. A thiazide derivative, hydrochlorothiazide is sold under the trade names Microzide® and Aquazide H. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis.

Legal Information

CERILLIANT is a registered trademark of Cerilliant Corporation
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Microzide is a registered trademark of Watson Laboratories, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Cerilliant Corporation

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (Example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Customers Also Viewed

Slide 1 of 3

1 of 3

Dexamethasone solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-085

Dexamethasone solution

Salbutamol

Sigma-Aldrich

S8260

Salbutamol

Phenacetin melting point standard Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1094

Phenacetin melting point standard

Successful rapid desensitization to hydrochlorothiazide.
Jamma Li et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 110(4), 307-308 (2013-03-29)
Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Brent Egan et al.
Journal of hypertension, 31(2), 259-260 (2013-01-11)
Yoshihisa Hanayama et al.
Acta medica Okayama, 66(6), 449-459 (2012-12-21)
Angiotensin receptor blockers (ARBs) are the first-line antihypertensive agents. In clinical practice, it is often difficult to achieve the recommended blood pressure level by ARBs in their ordinal dosages alone. This study examined the practical efficacy of a combination therapy
Alexander V Murray et al.
Journal of clinical hypertension (Greenwich, Conn.), 14(12), 821-827 (2012-12-05)
Combination antihypertensive therapies are recommended to attain blood pressure (BP) targets especially in high-risk patients in whom rapid and pronounced BP control is essential. This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination
Michael A Weber et al.
Lancet (London, England), 381(9866), 537-545 (2012-12-12)
In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal weight compared with obese individuals. As a prespecified analysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service